Expertise in
1
conditions

Shir-jing K. Ho

St George & Sutherland Clinical School, 
Sydney, NSW, AU 
Expertise in
1
conditions
St George & Sutherland Clinical School, 
Sydney, NSW, AU 

Overview

Shir-jing Ho practices practicing medicine in Sydney, Australia.

Ho is highly rated in 1 condition, according to our data. Their clinical expertise encompasses Marginal Zone Lymphoma (MZL), B-Cell Lymphoma, and Non-Hodgkin Lymphoma.

They are actively involved in clinical research, co-authoring 12 peer reviewed articles and participating in 2 clinical trials.

Locations

St George & Sutherland Clinical School, Sydney, NSW, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 2, Open-label Study of Zanubrutinib (BGB-3111) in Patients With Relapsed or Refractory Marginal Zone Lymphoma
A Phase 2, Open-label Study of Zanubrutinib (BGB-3111) in Patients With Relapsed or Refractory Marginal Zone Lymphoma
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug
Study Drug: Zanubrutinib
Study Phase: Phase 2
Coronavirus Outcomes Registries in Immunocompromised Individuals Australia (CORIA): a Multisite Registry and Optional Biorepository in People With COVID-19 and Selected Conditions Affecting Immune Function
Coronavirus Outcomes Registries in Immunocompromised Individuals Australia (CORIA): a Multisite Registry and Optional Biorepository in People With COVID-19 and Selected Conditions Affecting Immune Function
Enrollment Status: Unknown
Publish Date: September 01, 2021
View 1 Less Clinical Trial

12 Total Publications

Sequential high-dose methotrexate and cytarabine administration improves outcomes in real-world patients with primary central nervous system lymphoma: A report from the Australasian Lymphoma Alliance.
Sequential high-dose methotrexate and cytarabine administration improves outcomes in real-world patients with primary central nervous system lymphoma: A report from the Australasian Lymphoma Alliance.
Journal: EJHaem
Published: May 09, 2024

Frequently Asked Questions about Shir-jing K. Ho

Is Shir-jing K. Ho a top-rated expert for Marginal Zone Lymphoma (MZL)?

MediFind is an objective health platform that identifies experts based on real-world data. Shir-jing K. Ho is classified as an Distinguished expert for Marginal Zone Lymphoma (MZL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Shir-jing K. Ho participate in research or clinical trials?

Yes. Shir-jing K. Ho has published 12 articles and abstracts on conditions like Marginal Zone Lymphoma (MZL). You can view a list of Shir-jing K. Ho's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ho's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile